Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...
We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other best ...
PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis ...
The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...
AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.
Which cardiology drug companies could be attractive takeover candidates? Seeking Alpha analysts weigh in. Read more here.
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the ...
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
Bynder, a global leader in AI-powered enterprise DAM has announced its AI Agents, a suite of new AI innovations that will execute business-critical tasks such as content enrichment, discovery, ...
Forethought Introduces Voice, Becoming the First Complete Agentic AI Platform Across All CX Channels
Forethought, the leader in agentic AI for customer support, today announced the launch of Forethought Voice to its multi-agent, multi-channel AI for CX platform. "Agentic AI can now offer seamless ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback